Skip to main content

X4 Pharmaceuticals, Inc

XFOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001501697

In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 3 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $491.9M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by X4 Pharmaceuticals, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
3 insiders, $356.5K in total
Insiders trading
3
Net value
−$356.5K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for X4 Pharmaceuticals, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for X4 Pharmaceuticals, Inc
NameTitleLast reported holdingLast filingFilings, past year
Volpone JohnPresident265,305Aug 13, 20262
Craig Adam RExecutive Chairman328,651Aug 13, 20263
Kirske DavidChief Financial Officer167,750Jul 1, 20263
Gold KellyDirector–Jul 1, 20261
Bridger GaryDirector4,722Jan 7, 20261
Wyzga Michael SDirector5,555Jan 5, 20261
Stewart MurrayDirector7,883Jan 5, 20261
de Craecker FrancoiseDirector4,722Jan 5, 20261
Thoren Natasha FayChief Legal Officer9,462Jul 3, 20250
McGirr David W JDirector4,722Jun 10, 20250
Woods KeithDirector6,000Jun 10, 20250
Baldry MarkChief Commercial Officer25,337Jun 3, 20250
Mostafa Adam S.Chief Financial Officer850,000Feb 14, 20250
Ragan PaulaPresident and CEO3,337,386Feb 14, 20250
Arbet-Engels ChristopheChief Medical Officer864,207Feb 14, 20250
DiBiase MaryChief Operating Officer1,140,980Feb 14, 20250
Taveras ArthurChief Scientific Officer388,026Oct 8, 20240
Lawton Alison FrancesDirector96,667Jun 11, 20240
Aliski WilliamDirector96,667Jun 11, 20240
Meisner Derek MChief Legal Officer145,155Aug 19, 20220
Cadavid DiegoChief Medical Officer104,107Mar 1, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 13, 2026 (view filing)4:13 PM ETAug 121 dayVolpone JohnPresidentSSale−24.6K$4.44−$109.2K−8.5%265.3K after
Aug 13, 2026 (view filing)4:10 PM ETAug 121 dayCraig Adam RExecutive ChairmanSSale−47.4K$4.44−$210.8K−12.6%328.7K after
Jul 1, 2026 (view filing)4:23 PM ETJun 301 dayKirske DavidChief Financial OfficerSSale−8.54K$4.26−$36.4K−4.8%167.8K after
May 13, 2026 (view filing)May 121 dayKirske DavidChief Financial OfficerSSale−17.0K$4.29−$72.8K−8.8%176.3K after
Oct 27, 2025 (view filing)Oct 234 daysCraig Adam RExecutive ChairmanPPurchase+86.2K$2.90+$250.0K+29.7%376.1K after
Feb 14, 2025 (view filing)4:08 PM ETMay 17-Nov 15, 2024273 daysLateBaldry MarkChief Commercial OfficerPPurchase+35.0K$0.5493+$19.3K+37.2%129.2K after2 lots
Jan 27, 2025 (view filing)6:15 PM ETJan 243 daysRagan PaulaPresident and CEOSSale−76.5K$0.454−$34.7K−6.6%1.09M after
Jan 27, 2025 (view filing)6:15 PM ETJan 243 daysMostafa Adam S.Chief Financial OfficerSSale−74.8K$0.454−$33.9K−100.0%0 after
Jan 27, 2025 (view filing)6:15 PM ETJan 243 daysBaldry MarkChief Commercial OfficerSSale−29.2K$0.4541−$13.2K−23.7%94.1K after
Jan 27, 2025 (view filing)6:15 PM ETJan 243 daysDiBiase MaryChief Operating OfficerSSale−22.3K$0.4535−$10.1K−4.3%491.0K after
Jan 27, 2025 (view filing)6:15 PM ETJan 243 daysArbet-Engels ChristopheChief Medical OfficerSSale−11.6K$0.4546−$5.28K−45.0%14.2K after
Nov 19, 2024 (view filing)4:31 PM ETNov 154 daysRagan PaulaPresident and CEOSSale−31.9K$0.3945−$12.6K−3.1%993.9K after
Oct 16, 2024 (view filing)Oct 151 dayRagan PaulaPresident and CEOSSale−31.9K$0.56−$17.9K−3.0%1.03M after
Oct 8, 2024 (view filing)Oct 71 dayMostafa Adam S.Chief Financial OfficerSSale−230.6K$0.55−$126.9K−100.0%0 after
Oct 8, 2024 (view filing)Oct 71 dayBaldry MarkChief Commercial OfficerSSale−11.1K$0.58−$6.45K−18.7%48.5K after
Oct 8, 2024 (view filing)Oct 71 dayRagan PaulaPresident and CEOSSale−239.4K$0.55−$131.7K−18.5%1.06M after
Oct 8, 2024 (view filing)Oct 71 dayDiBiase MaryChief Operating OfficerSSale−67.7K$0.57−$38.6K−13.0%452.1K after
Oct 8, 2024 (view filing)Oct 71 dayTaveras ArthurChief Scientific OfficerSSale−76.9K$0.56−$43.1K−16.5%388.0K after
Sep 11, 2024 (view filing)Sep 92 daysDiBiase MaryChief Operating OfficerSSale−2.64K$0.66−$1.74K−0.9%289.1K after
Mar 11, 2024 (view filing)Mar 11Same dayTaveras ArthurChief Scientific OfficerSSale−14.2K$0.88−$12.5K−5.7%234.3K after
Mar 11, 2024 (view filing)Mar 11Same dayRagan PaulaPresident and CEOSSale−49.7K$0.88−$43.7K−6.1%765.1K after
Mar 11, 2024 (view filing)Mar 11Same dayMostafa Adam S.Chief Financial OfficerSSale−52.5K$0.88−$46.2K−100.0%0 after
Mar 11, 2024 (view filing)Mar 11Same dayDiBiase MaryChief Operating OfficerSSale−15.4K$0.88−$13.6K−5.0%291.8K after
Feb 12, 2024 (view filing)Feb 12Same dayDiBiase MaryChief Operating OfficerSSale−3.68K$1.01−$3.72K−1.2%307.2K after
Feb 12, 2024 (view filing)Feb 12Same dayTaveras ArthurChief Scientific OfficerSSale−787$1.01−$794.87−0.3%248.5K after
Feb 12, 2024 (view filing)Feb 12Same dayRagan PaulaPresident and CEOSSale−21.7K$1.01−$21.9K−2.6%814.7K after
Feb 12, 2024 (view filing)Feb 12Same dayMostafa Adam S.Chief Financial OfficerSSale−27.7K$1.01−$28.0K−34.6%52.5K after
Nov 3, 2023 (view filing)Nov 1-32 daysRagan PaulaPresident and CEOSSale−239.4K$0.7583−$181.6K−22.3%836.4K after2 lots10b5-1
Nov 3, 2023 (view filing)Nov 12 daysMostafa Adam S.Chief Financial OfficerSSale−230.6K$0.73−$168.4K−74.2%80.2K after10b5-1
Nov 3, 2023 (view filing)Nov 12 daysDiBiase MaryChief Operating OfficerSSale−67.7K$0.73−$49.4K−17.9%310.8K after10b5-1
Nov 3, 2023 (view filing)Nov 12 daysBaldry MarkChief Commercial OfficerSSale−10.3K$0.73−$7.49K−29.4%24.7K after10b5-1
Nov 3, 2023 (view filing)Nov 12 daysTaveras ArthurChief Scientific OfficerSSale−67.7K$0.73−$49.4K−21.4%249.3K after10b5-1
Sep 12, 2023 (view filing)Sep 84 daysDiBiase MaryChief Operating OfficerSSale−2.64K$1.25−$3.30K−1.8%147.9K after
Aug 22, 2023 (view filing)Aug 184 daysWyzga Michael SDirectorPPurchase+25.0K$1.20+$30.0K+48.4%76.7K after
Aug 11, 2023 (view filing)Aug 101 dayStewart MurrayInterim Chief Medical OfficerSSale−130.1K$1.06−$137.9K−47.0%146.5K after
Jul 5, 2023 (view filing)Jun 305 daysDiBiase MaryChief Operating OfficerSSale−464$1.89−$876.96−0.3%150.5K after
Jul 5, 2023 (view filing)Jun 305 daysMostafa Adam S.Chief Financial OfficerSSale−2.64K$1.89−$4.99K−3.2%80.2K after
Jun 26, 2023 (view filing)Jun 233 daysDiBiase MaryChief Operating OfficerSSale−857$1.93−$1.65K−0.6%151.0K after
Jun 26, 2023 (view filing)Jun 233 daysMostafa Adam S.Chief Financial OfficerSSale−5.42K$1.93−$10.5K−6.1%82.9K after
Jun 26, 2023 (view filing)Jun 233 daysRagan PaulaPresident and CEOSSale−6.72K$1.92−$12.9K−1.2%543.8K after
Jun 16, 2023 (view filing)Jun 151 dayDiBiase MaryChief Operating OfficerSSale−857$2.23−$1.91K−0.6%151.9K after
Jun 16, 2023 (view filing)Jun 151 dayMostafa Adam S.Chief Financial OfficerSSale−5.42K$2.22−$12.0K−5.8%88.3K after
Jun 16, 2023 (view filing)Jun 151 dayRagan PaulaPresident and CEOSSale−6.72K$2.23−$15.0K−1.2%550.5K after
May 31, 2023 (view filing)May 31Same dayRagan PaulaPresident and CEOSSale−6.29K$1.95−$12.3K−1.1%557.2K after
Mar 13, 2023 (view filing)Mar 103 daysDiBiase MaryChief Operating OfficerSSale−18.2K$0.84−$15.3K−10.6%152.7K after
Mar 13, 2023 (view filing)Mar 103 daysMostafa Adam S.Chief Financial OfficerSSale−52.5K$0.84−$44.1K−35.9%93.7K after
Mar 13, 2023 (view filing)Mar 103 daysTaveras ArthurChief Scientific OfficerSSale−16.8K$0.84−$14.1K−16.3%86.4K after
Mar 13, 2023 (view filing)Mar 103 daysRagan PaulaPresident and CEOSSale−49.7K$0.84−$41.7K−8.1%563.5K after
Feb 15, 2023 (view filing)Feb 132 daysTaveras ArthurChief Scientific OfficerSSale−928$0.93−$863.04−0.9%103.2K after
Feb 15, 2023 (view filing)Feb 132 daysDiBiase MaryChief Operating OfficerSSale−4.35K$0.93−$4.04K−2.5%170.9K after